Artal Group S.A. Has $5.98 Million Position in AnaptysBio, Inc. (ANAB)

Artal Group S.A. boosted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 459.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 250,000 shares of the biotechnology company’s stock after purchasing an additional 205,310 shares during the period. Artal Group S.A. owned about 1.23% of AnaptysBio worth $5,983,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Frazier Management LLC bought a new position in AnaptysBio in the first quarter valued at $102,354,000. Perceptive Advisors LLC bought a new position in AnaptysBio in the first quarter valued at $24,474,000. Marshall Wace North America L.P. bought a new position in AnaptysBio in the first quarter valued at $6,924,000. MARSHALL WACE ASIA Ltd bought a new position in AnaptysBio in the first quarter valued at $6,924,000. Finally, JPMorgan Chase & Co. bought a new position in AnaptysBio in the first quarter valued at $3,851,000. 71.35% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/19/artal-group-s-a-has-5-98-million-position-in-anaptysbio-inc-anab.html.

A number of analysts have commented on ANAB shares. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Monday, May 29th. Robert W. Baird started coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 price target for the company. Credit Suisse Group increased their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price target on shares of AnaptysBio in a research note on Tuesday, September 12th. Seven research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $36.86.

In related news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Holdings A/S Novo sold 356,300 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the sale, the insider now directly owns 1,936,604 shares in the company, valued at $40,862,344.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,133,940 shares of company stock valued at $24,223,316.

Shares of AnaptysBio, Inc. (ANAB) traded down 2.7360% during mid-day trading on Tuesday, reaching $34.8205. 75,776 shares of the company’s stock were exchanged. AnaptysBio, Inc. has a 52-week low of $15.17 and a 52-week high of $37.62. The company’s 50-day moving average price is $32.73 and its 200 day moving average price is $31.29. The company’s market cap is $708.32 million.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. On average, equities research analysts predict that AnaptysBio, Inc. will post ($1.98) EPS for the current year.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB).

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply